National and international guidelines for the management of dyslipidemias classically
recommend measuring lipid profiles after fasting for at least 8 h.[1]-[3] Lipid targets for assessing cardiovascular risk
traditionally rely on plasma total-cholesterol and low-density lipoprotein-cholesterol
(LDL-c) levels, with the latter being calculated by the Friedewald equation.[4]Some imprecision due to low or high triglycerides in calculating LDL-cholesterol may
affect cardiovascular risk assessment, the definition of a therapeutic target, and the
need to intensify the treatment.[5],[6]
Accurate results require triglyceride levels below 400 mg/dL, but above 100 mg/dL the
calculated LDL-c starts to be underestimated, when compared to ultracentrifugation
measurements. Another limitation to the use of the formula is that samples must not
contain beta-VLDL, as in the case of type III hyperlipoproteinemia. When one of these
conditions are not satisfied, the equation cannot be used due to imprecision.[5]-[7]Other lipid parameters, such as apolipoprotein-B and non-high-density
lipoprotein-cholesterol (non-HDL-C) reflect the pool of atherogenic lipoproteins and
have emerged as good markers to improve cardiovascular risk assessment, and also to
guide lipid-lowering therapy.[2],[3],[8],[9] These
variables can be used in both the fasting and non-fasting states, and non-fasting
lipoproteins are regarded as better atherosclerotic risk predictors, when compared with
fasting ones, for they reflect remnant, atherogenic lipoproteins, with higher
correlation with cardiovascular risk.[2],[3],[8],[9]To avoid the interference of triglycerides, direct measurements of LDL-cholesterol have
been developed.[10],[11]
but these techniques lack proper standardization, and were tested in few clinical trials
that use LDL-c as target.[12],[13]Since then, many papers, as result of important and broad studies, were carried out
comparing fasting and non-fasting lipid parameters, mainly total cholesterol, HDL-c,
LDL-c and triglycerides, concluding that non-fasting lipids do not clinically differ
from fasting ones, except for triglycerides, that require different reference values for
non-fasting state.[14],[15]Here we present a second opinion for what has been stated in the article:
“Flexibilization of fasting for laboratory determination of the lipid
profile in Brazil: science or convenience?”Our second opinion uses steps for building a scientific statement. The first step is to
find an issue of interest to be debated. The second step requires full understanding of
what is currently known about what is being explained. This basically deals with
scientific publications, citations seeking other scientific papers, and books on the
topic. Although it is possible to defer to the scientific consensus, you cannot really
have a personal scientific viewpoint on anything without understanding what current
research says about it.Keep in mind that all scientific papers should be found in peer-reviewed well-reputed
journals. It is best to approach scientific literature with no prior judgements;
however, it can be a difficult task. After reviewing all relevant papers to the matter,
it is possible to develop a scientific view and an opinion. If the scientific material
collected reaches the same conclusion, it is unlikely that you can hold a different
viewpoint at this moment. But, if some papers disagree, there is room for debate and to
raise a plausible second opinion, if there is good research supporting this view.
High-quality, well-designed studies, with a large number of participants, in the
opposite direction of what had been stated, do reinforce the validity
of a second opinion.This article will address the interpretation, applications and limitations of a
non-fasting lipid profile for daily clinical practice.First, large observational data, with population-based studies and registries, including
111,048 women, 98,132 men, 12,744 children, and patients with diabetes, in which
non-fasting lipid profiles were compared with those obtained under fasting conditions,
have demonstrated that the maximal changes in plasma lipids and lipoproteins occurred
between 1-6 hrs. after a usual meal. These trials have established that only minor
changes occurred in response to habitual food intake in the majority of
individuals.[14],[16]-[19]
Total cholesterol, LDL-c, remnant cholesterol, varied 8 mg/dL, whereas HDL-c,
apolipoprotein A1, apolipoprotein B, and lipoprotein(a) were not affected by
fasting/non-fasting status. These data were derived from the Women’s Health Study, the
Copenhagen General Population Study, the National Health and Nutrition Examination
Survey, and the Calgary Laboratory Services in Canada.[14],[16]-[19]Among all studies, only minor increases in plasma triglycerides and minor decreases in
total and LDL cholesterol concentrations were observed, in non-fasting conditions, with
no change in HDL cholesterol concentrations. In subjects with diabetes, calculated LDL-c
obtained 1-3 hours after a meal decreased 23 mg/dL, and could imply in statin withhold;
however, when corrected for albumin, reflecting fluid intake, the difference
disappeared, and was attributed to the fluid and not to the
diet.[20]Second, we live most of our time in non-fasting state. Non-fasting and fasting lipid
concentrations vary similarly over time and are at least equivalent in the prediction of
cardiovascular disease. In fact, data from the Calgary Laboratory Services in Canada
demonstrated that in ~200,000 men and women, total cholesterol, HDL and LDL-cholesterol
did not vary as a function of the period of fasting after the last meal.[17]Third, reference plasma lipid, lipoprotein, and apolipoprotein concentration values based
on desirable concentration cutoff points, do not vary when non-fasting, except for
triglycerides, which should be flagged as abnormal in laboratory reports > 175 mg/dL.
However, non-fasting triglycerides were better predictors than in the fasting
state.[7]Fourth, the risk of ischemic heart disease and myocardial infarction in 92,285
individuals from the Copenhagen General Population Study recruited from 2003 through
2014, could be predicted by non-fasting lipids (reported in Nordestgaard et
al.[7]).Fifth, a novel method to estimate LDL-C using an adjustable factor for the TG:VLDL-C
ratio provided a more accurate guideline risk classification than the Friedewald
equation.[21] The authors used a
large convenience sample of consecutive clinical lipid profiles obtained from 2009
through 2011 (n = 1,350,908), including children, adolescents, and adults in the United
States). The sample was randomly assigned to derivation (n = 900,605) or validation (n =
450,303) data sets. Results closely matched those in the National Health and Nutrition
Examination Survey (NHANES). This estimation method provided higher-fidelity estimates
than the Friedewald equation. The greatest improvement in concordance occurred when
classifying LDL-C lower than 70 mg/dL, especially in patients with high triglyceride
levels. Indeed, there is a need for external validation, and assessment of its clinical
importance. However, this novel method could be implemented in most laboratory reporting
systems with virtually no cost.Finally, what would be the problem to add convenience to science? Postprandial
measurements are more practical and provide the patient a greater access to the
laboratory, and also can decrease the number of missed working days and medical
appointments due to missed tests; blood collection in the postprandial state is safer in
several circumstances and help prevent hypoglycemia secondary to the use of insulin in
patients with diabetes mellitus, in pregnant women, children, and elderly individuals,
reducing complications and increasing adherence to the tests and to medical
appointments; flexibilization of fasting for lipid profiling, can bring more comfort to
the patient and greater amplitude of schedules in the laboratories, especially in the
morning; technological advances in diagnostic methods, can mitigate the interference of
sample turbidity when triglycerides are high.[22]If, fasting is not routinely required for assessing the plasma lipid profile, some
recommendations should be made in specific situations: 1) when non-fasting plasma
triglyceride concentration exceed 440 mg/dL, consideration should be given to repeating
the lipid profile in the fasting state; 2) laboratory reports should flag abnormal
values based on desirable concentration cut-off points; 3) life-threatening or extremely
high concentrations should trigger an immediate referral to a lipid clinic or to a
physician with special interest in lipids.[7],[22]
Authors: H T Xavier; M C Izar; J R Faria Neto; M H Assad; V Z Rocha; A C Sposito; F A Fonseca; J E dos Santos; R D Santos; M C Bertolami; A A Faludi; T L R Martinez; J Diament; A Guimarães; N A Forti; E Moriguchi; A C P Chagas; O R Coelho; J A F Ramires Journal: Arq Bras Cardiol Date: 2013-10 Impact factor: 2.000
Authors: Michael Miller; Neil J Stone; Christie Ballantyne; Vera Bittner; Michael H Criqui; Henry N Ginsberg; Anne Carol Goldberg; William James Howard; Marc S Jacobson; Penny M Kris-Etherton; Terry A Lennie; Moshe Levi; Theodore Mazzone; Subramanian Pennathur Journal: Circulation Date: 2011-04-18 Impact factor: 29.690
Authors: André Arpad Faludi; Maria Cristina de Oliveira Izar; José Francisco Kerr Saraiva; Ana Paula Marte Chacra; Henrique Tria Bianco; Abrahão Afiune; Adriana Bertolami; Alexandre C Pereira; Ana Maria Lottenberg; Andrei C Sposito; Antonio Carlos Palandri Chagas; Antonio Casella; Antônio Felipe Simão; Aristóteles Comte de Alencar; Bruno Caramelli; Carlos Costa Magalhães; Carlos Eduardo Negrão; Carlos Eduardo Dos Santos Ferreira; Carlos Scherr; Claudine Maria Alves Feio; Cristiane Kovacs; Daniel Branco de Araújo; Daniel Magnoni; Daniela Calderaro; Danielle Menosi Gualandro; Edgard Pessoa de Mello; Elizabeth Regina Giunco Alexandre; Emília Inoue Sato; Emilio Hideyuki Moriguchi; Fabiana Hanna Rached; Fábio César Dos Santos; Fernando Henpin Yue Cesena; Francisco Antonio Helfenstein Fonseca; Henrique Andrade Rodrigues da Fonseca; Hermes Toros Xavier; Isabela Cardoso Pimentel Mota; Isabela de Carlos Back Giuliano; Jaqueline Scholz Issa; Jayme Diament; João Bosco Pesquero; José Ernesto Dos Santos; José Rocha Faria; José Xavier de Melo; Juliana Tieko Kato; Kerginaldo Paulo Torres; Marcelo Chiara Bertolami; Marcelo Heitor Vieira Assad; Márcio Hiroshi Miname; Marileia Scartezini; Neusa Assumpta Forti; Otávio Rizzi Coelho; Raul Cavalcante Maranhão; Raul Dias Dos Santos; Renato Jorge Alves; Roberta Lara Cassani; Roberto Tadeu Barcellos Betti; Tales de Carvalho; Tânia Leme da Rocha Martinez; Viviane Zorzanelli Rocha Giraldez; Wilson Salgado Journal: Arq Bras Cardiol Date: 2017-07 Impact factor: 2.000
Authors: S Matthijs Boekholdt; Benoit J Arsenault; Samia Mora; Terje R Pedersen; John C LaRosa; Paul J Nestel; R John Simes; Paul Durrington; Graham A Hitman; K M A Welch; David A DeMicco; Aeilko H Zwinderman; Michael B Clearfield; John R Downs; Andrew M Tonkin; Helen M Colhoun; Antonio M Gotto; Paul M Ridker; John J P Kastelein Journal: JAMA Date: 2012-03-28 Impact factor: 56.272
Authors: M John Chapman; Henry N Ginsberg; Pierre Amarenco; Felicita Andreotti; Jan Borén; Alberico L Catapano; Olivier S Descamps; Edward Fisher; Petri T Kovanen; Jan Albert Kuivenhoven; Philippe Lesnik; Luis Masana; Børge G Nordestgaard; Kausik K Ray; Zeljko Reiner; Marja-Riitta Taskinen; Lale Tokgözoglu; Anne Tybjærg-Hansen; Gerald F Watts Journal: Eur Heart J Date: 2011-04-29 Impact factor: 29.983